Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Deferred Taxes (2022 - 2025)

GeneDx Holdings (WGS) has disclosed Deferred Taxes for 4 consecutive years, with $246000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Deferred Taxes rose 623.4% to $246000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $424000.0, a 158.08% increase, with the full-year FY2024 number at -$343000.0, up 62.96% from a year prior.
  • Deferred Taxes was $246000.0 for Q3 2025 at GeneDx Holdings, up from -$245000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $447000.0 in Q1 2025 to a low of -$49.1 million in Q2 2022.
  • A 4-year average of -$3.6 million and a median of -$123000.0 in 2022 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: plummeted 890.38% in 2023, then surged 645.12% in 2025.
  • GeneDx Holdings' Deferred Taxes stood at $52000.0 in 2022, then tumbled by 890.38% to -$411000.0 in 2023, then skyrocketed by 94.16% to -$24000.0 in 2024, then skyrocketed by 1125.0% to $246000.0 in 2025.
  • Per Business Quant, the three most recent readings for WGS's Deferred Taxes are $246000.0 (Q3 2025), -$245000.0 (Q2 2025), and $447000.0 (Q1 2025).